Brand names: Kerendia • Drug class: Nonsteroidal mineralocorticoid receptor antagonist
Finerenone is a new-generation mineralocorticoid receptor antagonist for diabetic kidney disease. The FIDELIO-DKD trial (NEJM 2020) showed it cuts kidney failure risk by 18% on top of ACEi/ARB — without the potassium and hormone side effects of older spironolactone.
In diabetic CKD, finerenone blocks aldosterone-driven inflammation and fibrosis in the kidney — reducing albuminuria by ~30% and slowing progression. It is the third pillar of diabetic kidney protection, after ACEi/ARB and SGLT2 inhibitors.
18% lower risk of kidney failure, sustained eGFR decline, or kidney death
FIDELIO-DKD (Bakris GL et al., NEJM 2020), 2020
~30% reduction in urine albumin-creatinine ratio within 4 months
FIDELIO-DKD, 2020
Consistent benefit in the broader FIGARO-DKD cardiovascular trial
FIGARO-DKD (Pitt B et al., NEJM 2021), 2021
10 mg or 20 mg once daily based on eGFR (20 mg if eGFR ≥60; 10 mg if 25-59). Start only if serum potassium ≤4.8 mEq/L. Monitor potassium at 1 month and then regularly. Use with caution below eGFR 25.
Check your kidney functionThis page is educational. Medication decisions — especially dosing changes — must be made by your prescribing clinician.
Advertisement
Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes and obesity. The FLOW trial (NEJM 2024) showe...
Learn moreSGLT2 inhibitors — originally diabetes drugs — are now a cornerstone of kidney disease treatment. DAPA-CKD and...
Learn moreDapagliflozin is the first SGLT2 inhibitor proven to protect kidneys in CKD with and without diabetes (DAPA-CK...
Learn moreEmpagliflozin is an SGLT2 inhibitor approved for CKD with albuminuria (eGFR ≥20) and heart failure. The EMPA-K...
Learn moreAdvertisement
This content is a general reference, not medical advice, a diagnosis, or a treatment plan. Do not change your diet, fluids, medicines, or dialysis plan without your nephrologist or renal dietitian. Individual recommendations depend on your labs, medications, conditions, and care plan.